Acly-KO Mouse
一般名
Acly-KO
製品ID
S-KO-17853
背景情報
C57BL/6JCya
系統ID
KOCMP-104112-Acly-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Acly-KO Mouse(カタログ番号S-KO-17853)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Acly-KO
系統ID
KOCMP-104112-Acly-B6J-VA
遺伝子名
製品ID
S-KO-17853
遺伝子別名
A730098H14Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 11
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000007131
NCBIトランスクリプトID
NM_134037
ターゲット領域
Exon 4~6
有効領域の大きさ
~2.5 kb
遺伝子研究の概要
Acly, also known as adenosine 5'-triphosphate citrate lyase, is a cytosolic enzyme that converts citrate into acetyl-coenzyme A. This reaction is crucial for fatty acid and cholesterol biosynthesis, linking carbohydrate to lipid metabolism [1,2]. It is also involved in protein acetylation, and its expression changes are related to hyperlipidemia, cardiovascular diseases, and cancer [8]. Genetic models, such as gene knockout (KO) or conditional knockout (CKO) mouse models, have been valuable in studying its functions.
In cancer research, ACLY inhibition in immunocompetent mice was found to up-regulate PD-L1 expression in cancer cells, inducing T-cell dysfunction and immunosuppression. However, it also overcame cancer resistance to anti-PD-L1 therapy in a cGAS-dependent manner, likely due to polyunsaturated fatty acid peroxidation and mitochondrial DNA leakage that activates the cGAS-STING pathway [1]. In lipid metabolism and atherosclerosis studies, ACLY deficiency in hepatocytes protected from hepatic steatosis and dyslipidemia. Pharmacological inhibition of ACLY by bempedoic acid prevented dyslipidemia and attenuated atherosclerosis in hypercholesterolemic mice and miniature pigs [2]. In colon cancer, ACLY-deficient cell lines showed attenuated migration and invasion abilities, and ACLY promoted metastasis by stabilizing CTNNB1 protein [3]. In non-alcoholic fatty liver disease (NAFLD), Hrd1 interacted with and ubiquitinated Acly, reducing its protein level and suppressing lipogenesis, with Hrd1 overexpression ameliorating hepatic steatosis in db/db mice [4]. In hepatic ischemia-reperfusion injury, hepatic deficiency of Acly exacerbated injury, while restoration of Acly nuclear localization in the steatotic liver ameliorated the injury [5]. In oocyte maturation, autophagy in granulosa cells selectively degraded ACLY to maintain citrate homeostasis and promote oocyte maturation [6]. In CD8 T-cell function, ablation of ACLY triggered an alternative acetate-dependent pathway for acetyl-CoA production, and ACLY and ACSS2 coordinated cytosolic acetyl-CoA production to maintain chromatin accessibility and T-cell effector function [7]. In experimental colitis, ACLY-deficient CD4+ T cells showed an impaired capacity to induce intestinal inflammation, and butyrate suppressed ACLY expression in T cells, with tributyrin ameliorating chronic colitis [9].
In conclusion, Acly plays essential roles in multiple biological processes, including lipid metabolism, cancer development, oocyte maturation, and immune cell function. Gene knockout or conditional knockout mouse models have been instrumental in revealing its functions in diseases such as cancer, atherosclerosis, NAFLD, hepatic ischemia-reperfusion injury, and experimental colitis, providing potential therapeutic targets for these conditions.
References:
1. Xiang, Wei, Lv, Hongwei, Xing, Fuxue, Yang, Wen, Wang, Hongyang. 2023. Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation. In Science advances, 9, eadi2465. doi:10.1126/sciadv.adi2465. https://pubmed.ncbi.nlm.nih.gov/38055816/
2. Feng, Xiaojun, Zhang, Lei, Xu, Suowen, Shen, Ai-Zong. 2019. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. In Progress in lipid research, 77, 101006. doi:10.1016/j.plipres.2019.101006. https://pubmed.ncbi.nlm.nih.gov/31499095/
3. Wen, Jun, Min, Xuejie, Shen, Mengqin, Liu, Jianjun, Zhao, Xiaoping. 2019. ACLY facilitates colon cancer cell metastasis by CTNNB1. In Journal of experimental & clinical cancer research : CR, 38, 401. doi:10.1186/s13046-019-1391-9. https://pubmed.ncbi.nlm.nih.gov/31511060/
4. Li, Kai, Zhang, Kaini, Wang, Hai, Liang, Xiubin, Su, Dongming. 2020. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice. In Metabolism: clinical and experimental, 114, 154349. doi:10.1016/j.metabol.2020.154349. https://pubmed.ncbi.nlm.nih.gov/32888949/
5. Gao, Wenbin, Zhang, Liping, Li, Ziru, Mulholland, Michael W, Zhang, Weizhen. 2023. Nuclear Acly protects the liver from ischemia-reperfusion injury. In Hepatology (Baltimore, Md.), 80, 1087-1103. doi:10.1097/HEP.0000000000000692. https://pubmed.ncbi.nlm.nih.gov/37983829/
6. He, Hainan, Wang, Junling, Mou, Xingmei, Zhou, Jilong, Miao, Yi-Liang. 2022. Selective autophagic degradation of ACLY (ATP citrate lyase) maintains citrate homeostasis and promotes oocyte maturation. In Autophagy, 19, 163-179. doi:10.1080/15548627.2022.2063005. https://pubmed.ncbi.nlm.nih.gov/35404187/
7. Kaymak, Irem, Watson, McLane J, Oswald, Brandon M, Roy, Dominic G, Jones, Russell G. 2024. ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses. In The Journal of experimental medicine, 221, . doi:10.1084/jem.20231820. https://pubmed.ncbi.nlm.nih.gov/39150482/
8. Granchi, Carlotta. 2022. ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective. In Expert opinion on therapeutic patents, 32, 731-742. doi:10.1080/13543776.2022.2067478. https://pubmed.ncbi.nlm.nih.gov/35436171/
9. Schulz-Kuhnt, Anja, Rühle, Katharina, Javidmehr, Asal, Neurath, Markus F, Atreya, Imke. 2024. ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo. In Gut, 73, 601-612. doi:10.1136/gutjnl-2023-330543. https://pubmed.ncbi.nlm.nih.gov/38176897/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
